Thomas S Corrigan

20220389341, Dec 8, 2022

Oct 1, 2020

17/787539

- Wickliffe OH, US
Scott Capitosti - Perry OH, US
Thomas S. Corrigan - Lakewood OH, US
David J. Aaserud - Painesville OH, US
Gregory Mathes - Streetsboro OH, US
Anthony R. Frank - Painesville OH, US
Elizabeth A. Schiferl - St. Paul MN, US
James C. Ray - Sevierville TN, US

C10L 1/222
C10L 10/14
C10L 1/2387
C10L 1/198

A composition comprising at least one fuel that is a diesel fuel, a biodiesel fuel, or combinations thereof and less than 100 ppm, less than 50 ppm (or less than 25 ppm, less than 10 ppm, 1 to 7 ppm, or 5 to 7 ppm) of an alkylene-coupled Cto C(or Cto C, Cto Cor Cto C) alkylphenol; 25 to 500 ppm (or 50 to 500 ppm, or 150 to 450 ppm or 250 to 450 ppm, or 250 to 400 ppm) of a terpolymer; and 5 to 90 ppm, (or 10 to 70 ppm, to 60 ppm, or 10 to 55 ppm) of hydrocarbyl-substituted amine detergent having at least one tertiary amino group.Methods of reducing the cold filter plugging point (“CFPP”) of a fuel, said method comprising adding the following components: less than 100 ppm, less than 50 ppm (or less than 25 ppm; less than 10 ppm, 1 to 7 ppm, or 5 to 7 ppm) of an alkylene-coupled Cto C(or Cto C, Cto Cor Cto C) alkylphenol; 25 to 500 ppm (or 50 to 500 ppm, or 150 to 450 ppm or 250 to 450 ppm, or 250 to 400 ppm) of a terpolymer; and 5 to 90 ppm, (or 10 to 70 ppm, to 60 ppm, or 10 to 55 ppm) of hydrocarbyl-substituted amine detergent having at least one tertiary amino group.Uses of a fuel additive composition to reduce the cold filter plugging point (“CFPP”) of a fuel, wherein the fuel additive composition comprises: 0.2 to 3 wt % of an alkylene-coupled Cto C(or Cto C, Cto Cor Cto C) alkylphenol; 10 to 50 wt % of a terpolymer; and 2 to 10 wt % of hydrocarbyl-substituted amine detergent having at least one tertiary amino group; and an optional solvent.

20220204472, Jun 30, 2022

Mar 10, 2022

17/691745

- Columbus OH, US
Christopher Callam - Blacklick OH, US
Jeremy Beck - Columbus OH, US
Qinggeng Zhuang - Columbus OH, US
Andrew Franjesevic - Columbus OH, US
Thomas Corrigan - Columbus OH, US
Craig McElroy - Lancaster OH, US

C07D 401/06
C07D 213/65
C07D 401/14
C07D 413/06

Disclosed herein are compounds, compositions, and methods for reactivating or realkylating aged acetylcholinesterase inhibited by or conjugated to the organophosphorus compound. The organophosphorus compound can be a nerve agent. The acetylcholinesterase can be in the central nerve system (CNS) and/or the peripheral nervous system (PNS) of a subject. Accordingly, methods for ameliorating, diminishing, reversing, treating or preventing the toxic effects of an organophosphorus compound in a subject are provided herein. Methods for prophylactic or therapeutic treatment of exposure to an organophosphorus nerve agent are also provided.

20230002697, Jan 5, 2023

Oct 1, 2020

17/779809

- Wickliffe OH, US
William R.S. Barton - Belper, Derbyshire, GB
Thomas S. Corrigan - Lakewood OH, US
Sona Sivakova - Painesville OH, US

C10M 129/70
C10M 129/72

The disclosed technology relates to lubricants for driveline and industrial gears containing a mono-ester or a mixture of mono- and di-esters, as well as a method of lubricating driveline and industrial gears with such a lubricant.

20200010448, Jan 9, 2020

Feb 15, 2018

16/486448

- Columbus OH, US
Christopher CALLAM - Blacklick OH, US
Jeremy BECK - Columbus OH, US
Qinggeng ZHUANG - Columbus OH, US
Andrew FRANJESEVIC - Columbus OH, US
Thomas CORRIGAN - Columbus OH, US
Craig MCELROY - Lancaster OH, US

C07D 401/06
C07D 213/65
C07D 413/06
C07D 401/14

Disclosed herein are compounds, compositions, and methods for reactivating or realkylating aged acetylcholinesterase inhibited by or conjugated to the organophosphorus compound. The organophosphorus compound can be a nerve agent. The acetylcholinesterase can be in the central nerve system (CNS) and/or the peripheral nervous system (PNS) of a subject. Accordingly, methods for ameliorating, diminishing, reversing, treating or preventing the toxic effects of an organophosphorus compound in a subject are provided herein. Methods for prophylactic or therapeutic treatment of exposure to an organophosphorus nerve agent are also provided.

20190055283, Feb 21, 2019

Feb 28, 2017

16/080781

- Columbus OH, US
Christopher HADAD - Dublin OH, US
Thomas CORRIGAN - Columbus OH, US

C07K 5/02
A61P 35/00
C07K 7/02
A61P 25/28

The present disclosure relates to compositions for inhibiting proteases, methods for synthesizing the compositions, and methods of using the disclosed protease inhibitors. Aspects of the invention include aza-peptide aldehyde and ketone compositions that inhibit proteases. The disclosed compounds, pharmaceutically acceptable salts, pharmaceutically acceptable derivatives, prodrugs, or combinations thereof can be used to treat disease or pathological conditions related to the activity of proteases associated with a specific disease or condition.